Scott R Garrison1, Lee Green2, Michael R Kolber2, Christina S Korownyk2, Nicole M Olivier2, Balraj S Heran3, Mary E Flesher4, G Michael Allan2. 1. Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada scott.garrison@ualberta.ca. 2. Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada. 3. Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada. 4. Fraser Health Authority, Burnaby, British Columbia, Canada.
Abstract
PURPOSE: Without supporting evidence, clinicians commonly recommend that warfarin be taken in the evening. We conducted a randomized controlled trial to evaluate the effect of administration time (morning vs evening) on the stability of warfarin's anticoagulant effect. METHODS: A total of 236 primary care physicians serving 54 western Canadian communities mailed letters of invitation to all their warfarin-using patients. Eligible patients were community-dwelling warfarin users (any indication) with at least 3 months of evening warfarin use and no plans for discontinuation. Participants were randomized (by web-based allocation) to morning vs continued evening warfarin ingestion. We used the Rosendaal method to determine the proportion of time within therapeutic range (TTR) of the international normalized ratio (INR) blood test month 2 to 7 postrandomization vs the 6 months prerandomization. The primary outcome was the percent change in proportion of time outside target INR range (with an a priori minimum clinically important difference of ±20%). All analyses were intention to treat. RESULTS: Between March 8, 2015 and September 30, 2016, we randomized 109 participants to morning and 108 to evening warfarin use. TTR rose from 71.8% to 74.7% in the morning group, and from 72.6% to 75.6% in the evening group, for a change in TTR of 2.9% in the former vs 3.0% in the latter (difference, -0.1%; P = .97; 95% CI for the difference, -6.1% to 5.9%). The difference in percent change in proportion of time outside the therapeutic INR range (obtained via Hodges-Lehmann estimation of the difference in medians) was 4.4% (P = .62; 95% CI for the difference, -17.6% to 27.3%). CONCLUSIONS: Administration time has no statistically significant nor clinically important impact on the stability of warfarin's anticoagulant effect. Patients should take warfarin whenever regular compliance would be easiest.
RCT Entities:
PURPOSE: Without supporting evidence, clinicians commonly recommend that warfarin be taken in the evening. We conducted a randomized controlled trial to evaluate the effect of administration time (morning vs evening) on the stability of warfarin's anticoagulant effect. METHODS: A total of 236 primary care physicians serving 54 western Canadian communities mailed letters of invitation to all their warfarin-using patients. Eligible patients were community-dwelling warfarin users (any indication) with at least 3 months of evening warfarin use and no plans for discontinuation. Participants were randomized (by web-based allocation) to morning vs continued evening warfarin ingestion. We used the Rosendaal method to determine the proportion of time within therapeutic range (TTR) of the international normalized ratio (INR) blood test month 2 to 7 postrandomization vs the 6 months prerandomization. The primary outcome was the percent change in proportion of time outside target INR range (with an a priori minimum clinically important difference of ±20%). All analyses were intention to treat. RESULTS: Between March 8, 2015 and September 30, 2016, we randomized 109 participants to morning and 108 to evening warfarin use. TTR rose from 71.8% to 74.7% in the morning group, and from 72.6% to 75.6% in the evening group, for a change in TTR of 2.9% in the former vs 3.0% in the latter (difference, -0.1%; P = .97; 95% CI for the difference, -6.1% to 5.9%). The difference in percent change in proportion of time outside the therapeutic INR range (obtained via Hodges-Lehmann estimation of the difference in medians) was 4.4% (P = .62; 95% CI for the difference, -17.6% to 27.3%). CONCLUSIONS: Administration time has no statistically significant nor clinically important impact on the stability of warfarin's anticoagulant effect. Patients should take warfarin whenever regular compliance would be easiest.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Harvey D White; Michael Gruber; Jan Feyzi; Scott Kaatz; Hung-Fat Tse; Steen Husted; Gregory W Albers Journal: Arch Intern Med Date: 2007-02-12
Authors: Elaine M Hylek; Alan S Go; Yuchiao Chang; Nancy G Jensvold; Lori E Henault; Joe V Selby; Daniel E Singer Journal: N Engl J Med Date: 2003-09-11 Impact factor: 91.245
Authors: Robby Nieuwlaat; John W Eikelboom; Sam Schulman; Harriette G C van Spall; Karleen M Schulze; Benjamin J Connolly; Spencer M Cuddy; Lowiek M Hubers; Alexander C Stehouwer; Stuart J Connolly Journal: J Thromb Thrombolysis Date: 2014-05 Impact factor: 2.300
Authors: Yi Wan; Carl Heneghan; Rafael Perera; Nia Roberts; Jennifer Hollowell; Paul Glasziou; Clare Bankhead; Yongyong Xu Journal: Circ Cardiovasc Qual Outcomes Date: 2008-11-05